NVSEF - IPO Update: Forma Therapeutics Readies $200 Million IPO
Quick Take
Forma Therapeutics Holdings (FMTX) intends to raise $200 million in an IPO of its voting common stock, per an amended registration statement.
The company is developing a pipeline of drug candidates for the treatment of various hematologic (blood) diseases and cancers.
FMTX has collaboration and investment relationships with four major biopharma firms and the IPO is priced within the typical range for biopharma IPOs.
Company & Technology
Watertown, Massachusetts-based Forma was founded to advance a pipeline of drug treatments, the lead candidate of which seeks to treat patients with sickle cell